Zacks: Analysts Set $114.00 Target Price for Cantel Medical Corp. (CMD)

Shares of Cantel Medical Corp. (NYSE:CMD) have earned an average broker rating score of 2.00 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. Cantel Medical’s rating score has improved by 20% from three months ago as a result of various analysts’ upgrades and downgrades.

Brokers have set a 12 month consensus price objective of $114.00 for the company and are expecting that the company will post $0.60 EPS for the current quarter, according to Zacks. Zacks has also assigned Cantel Medical an industry rank of 88 out of 257 based on the ratings given to related companies.

CMD has been the topic of a number of research reports. Sidoti decreased their price objective on Cantel Medical from $142.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, September 28th. ValuEngine lowered Cantel Medical from a “buy” rating to a “hold” rating in a report on Friday, September 28th. Finally, Raymond James decreased their price objective on Cantel Medical from $115.00 to $108.00 and set an “outperform” rating on the stock in a report on Friday, September 28th.

NYSE CMD traded up $0.99 on Friday, reaching $84.28. The stock had a trading volume of 180,301 shares, compared to its average volume of 257,387. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.51 and a quick ratio of 1.71. Cantel Medical has a 1-year low of $77.59 and a 1-year high of $130.92. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of 33.58 and a beta of 1.10.

Cantel Medical (NYSE:CMD) last issued its quarterly earnings data on Thursday, September 27th. The company reported $0.62 EPS for the quarter, meeting analysts’ consensus estimates of $0.62. Cantel Medical had a return on equity of 16.99% and a net margin of 10.44%. The firm had revenue of $228.85 million for the quarter, compared to analyst estimates of $227.10 million. On average, equities analysts anticipate that Cantel Medical will post 2.6 earnings per share for the current fiscal year.

About Cantel Medical

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.

Featured Story: How is the S&P 500 index different from the DJIA?

Get a free copy of the Zacks research report on Cantel Medical (CMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with's FREE daily email newsletter.

Leave a Reply